drug

Dextromethorphan

MeSH D003915
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by All India Institute of Medical Sciences, Bhubaneswar
3 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

3
Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia
NCT05944510Phase 4Completed
Pilot Study Using an NMDA Antagonist to Modulate Transcranial Direct Current Stimulation (tDCS) Effects on Sensory Discrimination
NCT02426983Phase 1, Phase 2Unknown
Add-On Therapy to Risperidonein Schizophrenia
NCT01189006Phase 2, Phase 3Completed

KOLs & investigators

3
Danielle Impey, Ph.D. (cand.)
Ru-Band Lu, MD
DEBASISH HOTA, D.M.

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
All India Institute of Medical Sciences, Bhubaneswar
company
trial
Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia
PHASE4
trial
Pilot Study Using an NMDA Antagonist to Modulate Transcranial Direct Current Stimulation (tDCS) Effects on Sensory Discrimination
PHASE1, PHASE2
trial
Add-On Therapy to Risperidonein Schizophrenia
PHASE2, PHASE3
trial
indication
Schizophrenia
indication
Schizophrenia
indication
Schizophrenia, Treatment-Resistant
indication
Treatment Resistant Schizophrenia
indication
KOL
Danielle Impey, Ph.D. (cand.)
KOL score —
person
Ru-Band Lu, MD
KOL score —
person
DEBASISH HOTA, D.M.
KOL score —
person